{"content":"<li class=\"n-box-item date-title\" data-end=\"1473911999\" data-start=\"1473825600\" data-txt=\"Sunday, December 22, 2019\">Wednesday, September 14, 2016</li><li class=\"n-box-item sa-box-item\" data-id=\"3208883\" data-ts=\"1473899321\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBLK\" target=\"_blank\">SBLK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208883-star-bulk-pushes-back-224m-in-loans-two-years-launches-equity-raise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Star Bulk pushes back $224M in loans by two years, launches equity raise</a></h4><ul>\n<li>Star Bulk Carriers (NASDAQ:<a href=\"https://seekingalpha.com/symbol/SBLK\" title=\"Star Bulk Carriers Corp.\">SBLK</a>) <font color=\"red\">-4.7%</font> AH after reporting a slightly larger than expected <a href=\"https://seekingalpha.com/news/3208826-star-bulk-carriers-misses-0_03-beats-revenue\" target=\"_blank\">Q2 loss</a> and announcing a $51.5M common stock offering to be used for general corporate purposes.</li>\n<li>SBLK also says it reached an agreement with its lenders to defer all debt repayment, totaling $223.9M, for 25  months to June 30, 2018 and to waive or substantially relax the  financial covenants of its debt facilities until year-end 2019.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3208883\" data-linked=\"Star Bulk pushes back $224M in loans by two years, launches equity raise\" data-tweet=\"$SBLK - Star Bulk pushes back $224M in loans by two years, launches equity raise https://seekingalpha.com/news/3208883-star-bulk-pushes-back-224m-in-loans-two-years-launches-equity-raise?source=tweet\" data-url=\"https://seekingalpha.com/news/3208883-star-bulk-pushes-back-224m-in-loans-two-years-launches-equity-raise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208874\" data-ts=\"1473893564\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UUUU\" target=\"_blank\">UUUU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208874-energy-fuels-launches-10m-bought-deal-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy Fuels launches $10M bought deal offering</a></h4><ul>     <li>Energy Fuels (NYSEMKT:<a href=\"https://seekingalpha.com/symbol/UUUU\" title=\"Energy Fuels Inc\">UUUU</a>) <font color=\"red\">-22.4%</font> AH after announcing a $10M bought deal offering of more than 5.55M units, each consisting of one common share and  a half-share purchase warrant at $1.80 each.</li>\n<li>The company says it plans to use the proceeds to continue to  finance the previously announced shaft sinking and evaluation at the  high-grade Canyon mine project in Arizona, continue to fund wellfield  construction at the Nichols Ranch Project in Wyoming, pay down debt, and for other corporate  needs.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3208874\" data-linked=\"Energy Fuels launches $10M bought deal offering\" data-tweet=\"$UUUU - Energy Fuels launches $10M bought deal offering https://seekingalpha.com/news/3208874-energy-fuels-launches-10m-bought-deal-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3208874-energy-fuels-launches-10m-bought-deal-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208864\" data-ts=\"1473889083\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208864-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li>\n<b>Top gainers, as of 5.25 p.m.:</b> <a href=\"https://seekingalpha.com/symbol/AERI\" title=\"Aerie Pharmaceuticals, Inc.\">AERI</a> <font color=\"green\">+65.6%</font>. <a href=\"https://seekingalpha.com/symbol/ACTG\" title=\"Acacia Research Corporation\">ACTG</a> <font color=\"green\">+14.5%</font>. <a href=\"https://seekingalpha.com/symbol/ACRX\" title=\"AcelRx Pharmaceuticals, Inc.\">ACRX</a> <font color=\"green\">+12.8%</font>. <a href=\"https://seekingalpha.com/symbol/APOG\" title=\"Apogee Enterprises, Inc.\">APOG</a> <font color=\"green\">+6.0%</font>. <a href=\"https://seekingalpha.com/symbol/LAKE\" title=\"Lakeland Industries, Inc.\">LAKE</a> <font color=\"green\">+5.5%</font>.</li>\n<li>\n<b>Top losers, as of 5.25p.m.:</b> <a href=\"https://seekingalpha.com/symbol/SBLK\" title=\"Star Bulk Carriers Corp.\">SBLK</a> <font color=\"red\">-4.3%</font>. <a href=\"https://seekingalpha.com/symbol/ARLZ-OLD\" title=\"Aralez Pharmaceuticals Inc.\">ARLZ-OLD</a> <font color=\"red\">-3.9%</font>. <a href=\"https://seekingalpha.com/symbol/QUOT\" title=\"Quotient Technology Inc.\">QUOT</a> <font color=\"red\">-2.4%</font>. <a href=\"https://seekingalpha.com/symbol/SRPT\" title=\"Sarepta Therapeutics, Inc.\">SRPT</a> <font color=\"red\">-1.8%</font>. TCK <font color=\"red\">-1.7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3208864\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$AERI $ACTG $ACRX - After Hours Gainers / Losers https://seekingalpha.com/news/3208864-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3208864-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:38 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208853\" data-ts=\"1473886495\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VMEM\" target=\"_blank\">VMEM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208853-violin-memory-issues-going-concern-warning-revenue-margin-expenditure-and-financing-obstacles\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Violin Memory issues going concern warning; revenue, margin, expenditure and financing obstacles cited</a></h4><ul>\n<li>Maintained deficit of $603.3M as of July 31.</li>\n<li>Expects net losses and negative cash flows from operations for at least the upcoming twelve months.</li>\n<li>Violin Memory (NYSE:<a href=\"https://seekingalpha.com/symbol/VMEM\" title=\"Violin Memory, Inc.\">VMEM</a>) has been under pressure since its inception and with its most recent <a href=\"https://seekingalpha.com/filing/3225170\" target=\"_blank\">unfavorable quarterly report</a>, continues on an acute decline.</li>\n<li>The company had <a href=\"https://seekingalpha.com/news/3208779-violin-memory-plus-10-percent-releases-new-flash-arrays-amid-recent-share-dive\" target=\"_blank\">announced</a> new flash array products earlier today and was trading <font color=\"green\">10% higher</font> throughout the session.</li>\n<li><a href=\"https://seekingalpha.com/filing/3225170\" target=\"_blank\">10-Q filing</a></li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3208853\" data-linked=\"Violin Memory issues going concern warning; revenue, margin, expenditure and financing obstacles cited\" data-tweet=\"$VMEM - Violin Memory issues going concern warning; revenue, margin, expenditure and financing obstacles cited https://seekingalpha.com/news/3208853-violin-memory-issues-going-concern-warning-revenue-margin-expenditure-and-financing-obstacles?source=tweet\" data-url=\"https://seekingalpha.com/news/3208853-violin-memory-issues-going-concern-warning-revenue-margin-expenditure-and-financing-obstacles\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208845\" data-ts=\"1473885163\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APOG\" target=\"_blank\">APOG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208845-apogee-beats-0_10-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apogee beats by $0.10, beats on revenue</a></h4><ul>\n<li>Apogee (NASDAQ:<a href=\"https://seekingalpha.com/symbol/APOG\" title=\"Apogee Enterprises, Inc.\">APOG</a>): FQ2 EPS of $0.77 <font color=\"green\">beats by $0.10</font>.</li>\n<li>Revenue of $278.5M (+15.7% Y/Y) <font color=\"green\">beats by $10.45M</font>.</li>\n<li>Shares <font color=\"green\">+4%</font>.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3208845\" data-linked=\"Apogee beats by $0.10, beats on revenue\" data-tweet=\"$APOG - Apogee beats by $0.10, beats on revenue https://seekingalpha.com/news/3208845-apogee-beats-0_10-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3208845-apogee-beats-0_10-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208843\" data-ts=\"1473884901\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STB\" target=\"_blank\">STB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208843-student-transportation-beats-0_02-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Student Transportation beats by $0.02, beats on revenue</a></h4><ul>\n<li>Student Transportation (NASDAQ:<a href=\"https://seekingalpha.com/symbol/STB\" title=\"Student Transportation Inc\">STB</a>): FQ4 EPS of $0.07 <font color=\"green\">beats by $0.02</font>.</li>\n<li>Revenue of $166.19M (+9.0% Y/Y) <font color=\"green\">beats by $2.52M</font>.</li>\n<li>Shares <font color=\"green\">+5%</font>.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3208843\" data-linked=\"Student Transportation beats by $0.02, beats on revenue\" data-tweet=\"$STB - Student Transportation beats by $0.02, beats on revenue https://seekingalpha.com/news/3208843-student-transportation-beats-0_02-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3208843-student-transportation-beats-0_02-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:28 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208827\" data-ts=\"1473884718\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AERI\" target=\"_blank\">AERI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208827-aerie-pharmas-roclatan-successful-in-late-stage-study-shares-up-67-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aerie Pharma&#39;s Roclatan successful in late-stage study; shares up 67% after hours</a></h4><ul>\n<li>Aerie Pharmaceuticals (NASDAQ:<a href=\"https://seekingalpha.com/symbol/AERI\" title=\"Aerie Pharmaceuticals, Inc.\">AERI</a>) is up <font color=\"green\">67%</font> after hours on robust volume in response to its <a href=\"https://www.sec.gov/Archives/edgar/data/1337553/000119312516709634/d248088dex991.htm\" target=\"_blank\">announcement</a> of successful results in a Phase 3 clinical trial, Mercury 1, assessing Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% for lowering intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.</li>\n<li>The study met its primary endpoint of showing superiority over each of its components, Rhopressa (netarsudil ophthalmic solution) 0.02% and latanoprost, as measured by baseline IOPs from above 20 to below 36 mmHg for each of nine time points. In addition, Roclatan lowered average IOP to 16 mmHg or lower in 61% of patients, significantly higher that the comparator arms. Normal eye pressure ranges from 12 - 22 mmHg.</li>\n<li>Management will host a conference call today at 5:00 pm ET to discuss the results.</li>\n<li>Read now <a href=\"https://seekingalpha.com/article/3982234-aerie-pharma-80-percent-upside-moon-shot-awaits\" target=\"_blank\">Aerie Pharma: 80% Upside While The Moon Shot Awaits </a>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3208827\" data-linked=\"Aerie Pharma&#39;s Roclatan successful in late-stage study; shares up 67% after hours\" data-tweet=\"$AERI - Aerie Pharma&#39;s Roclatan successful in late-stage study; shares up 67% after hours https://seekingalpha.com/news/3208827-aerie-pharmas-roclatan-successful-in-late-stage-study-shares-up-67-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3208827-aerie-pharmas-roclatan-successful-in-late-stage-study-shares-up-67-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208814\" data-ts=\"1473883153\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CKHUY\" target=\"_blank\">CKHUY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208814-partners-buy-sell-option-in-italian-wireless-merger\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Partners have buy-sell option in Italian wireless merger</a></h4><ul>   <li>New Italian wireless partners CK Hutchison (<a href=\"https://seekingalpha.com/symbol/CKHUY\" title=\"CK Hutchison Holdings LTD ADR\">OTCPK:CKHUY</a> <font color=\"green\">+1.3%</font>) and VimpelCom (<a href=\"https://seekingalpha.com/symbol/VIP\" target=\"_blank\">VIP</a> <font color=\"red\">-1.9%</font>) have a <a href=\"http://www.reuters.com/article/us-hutchison-vimpelcom-putoption-idUSKCN11K23K\" target=\"_blank\">buy-sell option in their joint venture</a>, starting three years after the conclusion of a deal merging their in-country divisions.</li>    <li>The two agreed to combine Three Italia and Wind Telecomunicazioni after lengthy negotiations, in order to better compete with Telecom Italia and Vodafone. A market entry from Iliad will return the market to four players.</li>    <li>A slide in a VimpelCom presentation notes the mechanism available to the parties, reportedly there in case of a deadlock on decisions.</li>    <li>The merger is set to complete in Q4.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3208768-iliads-aggressive-italy-plan-does-worry-telecom-italia\" target=\"_blank\">Iliad's aggressive Italy plan 'does not worry' Telecom Italia</a> (Sep. 14 2016)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3208814\" data-linked=\"Partners have buy-sell option in Italian wireless merger\" data-tweet=\"$CKHUY $CKHUY $VEON - Partners have buy-sell option in Italian wireless merger https://seekingalpha.com/news/3208814-partners-buy-sell-option-in-italian-wireless-merger?source=tweet\" data-url=\"https://seekingalpha.com/news/3208814-partners-buy-sell-option-in-italian-wireless-merger\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208820\" data-ts=\"1473883041\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WPT\" target=\"_blank\">WPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208820-stifel-upgrades-partnerships-wpt-ns-oks-dm-to-buy-from-hold\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stifel upgrades partnerships WPT, NS, OKS, DM to Buy from Hold</a></h4><ul>     <li>World Point Terminals (<a href=\"https://seekingalpha.com/symbol/WPT\" title=\"World Point Terminals, LP\">WPT</a> <font color=\"green\">+2.7%</font>) is <a href=\"http://www.streetinsider.com/Upgrades/Stifel+Upgrades+World+Point+Terminals+%28WPT%29+to+Buy/12030217.html\" target=\"_blank\">upgraded to Buy</a> from Hold with a $16 price target at Stifel, which believes WPT provides stable assets and distributions at an attractive price.</li>     <li>Stifel says WPT's asset  base, while small and scattered, is steady and largely fee-based, and the partnership has a solid track record of paying  $0.30/quarter with coverage typically at 1.2x-1.3x, for a current 8.3% yield.</li>     <li>The firm also upgrades NuStar Energy (<a href=\"https://seekingalpha.com/symbol/NS\" title=\"NuStar Energy L.P.\">NS</a> <font color=\"green\">+0.7%</font>), ONEOK Partners (OKS <font color=\"green\">+1.2%</font>) and Dominion Midstream Partners (<a href=\"https://seekingalpha.com/symbol/DM\" title=\"Dominion Midstream Partners LP\">DM</a> <font color=\"red\">-0.5%</font>) to Buy from Hold, citing current valuations and yields that provide strong risk/return profiles.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3208820\" data-linked=\"Stifel upgrades partnerships WPT, NS, OKS, DM to Buy from Hold\" data-tweet=\"$WPT $WPT $NS - Stifel upgrades partnerships WPT, NS, OKS, DM to Buy from Hold https://seekingalpha.com/news/3208820-stifel-upgrades-partnerships-wpt-ns-oks-dm-to-buy-from-hold?source=tweet\" data-url=\"https://seekingalpha.com/news/3208820-stifel-upgrades-partnerships-wpt-ns-oks-dm-to-buy-from-hold\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208812\" data-ts=\"1473883039\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208812-verizon-iphone-7-pre-orders-within-usual-range-higher-and-t\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verizon iPhone 7 pre-orders within usual range, higher at AT&amp;T</a></h4><ul>\n<li>Following strong T-Mobile and Sprint order pattern <a href=\"https://seekingalpha.com/news/3208435-apple-plus-3-percent-carrier-iphone-7-pre-orders-encouraging\" target=\"_blank\">statements</a> yesterday, AT&amp;T's CFO notes <a href=\"https://twitter.com/WaltBTIG/status/776123842901241857\" target=\"_blank\">volumes are up</a> while Verizon's Marni Walden labels the situation <a href=\"http://www.cnbc.com/2016/09/14/apple-stock-pares-gains-after-verizon-att-iphone-7-chatter.html\" target=\"_blank\">business as usual</a>.</li>\n<li>Walden indicates Verizon had access (as did AT&amp;T) to the iPhone before T-Mobile or Sprint and counts a larger base to compare figures against because of it.</li>\n<li>Nonetheless, Apple (<a href=\"https://seekingalpha.com/symbol/AAPL\" title=\"Apple Inc.\">AAPL</a> <font color=\"green\">+3.7%</font>) continues rising to <a href=\"https://seekingalpha.com/news/3208730-apple-shares-continue-torrid-run-headlines-shift-tax-complications-new-products\" target=\"_blank\">5-month highs</a> and is firmly back above a $600B+ market cap ($617.54B).</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3208812\" data-linked=\"Verizon iPhone 7 pre-orders within usual range, higher at AT&amp;T\" data-tweet=\"$AAPL - Verizon iPhone 7 pre-orders within usual range, higher at AT&amp;T https://seekingalpha.com/news/3208812-verizon-iphone-7-pre-orders-within-usual-range-higher-and-t?source=tweet\" data-url=\"https://seekingalpha.com/news/3208812-verizon-iphone-7-pre-orders-within-usual-range-higher-and-t\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>108&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208809\" data-ts=\"1473883019\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACER\" target=\"_blank\">ACER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208809-opexa-longs-head-for-exits-ahead-of-roche-data-presentation-for-ms-candidate-ocrelizumab\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Opexa longs head for the exits ahead of Roche data presentation for MS candidate ocrelizumab; shares down 22%</a></h4><ul>\n<li>Thinly traded nano cap Opexa Therapeutics (OPXA <font color=\"red\">-22.2%</font>) slumps on more than an 8x surge in volume, albeit on turnover of only 406K shares, as investors reportedly hit the sell button over concerns that Roche's (<a href=\"https://seekingalpha.com/symbol/RHHBY\" title=\"Roche Holding Ltd ADR\">OTCQX:RHHBY</a>) multiple sclerosis (MS) candidate OCREVUS (ocrelizumab) will hit the U.S. market before Tcelna. If, indeed, this is the reason for the exodus, investors must have been asleep for some time. The FDA's action date (PDUFA) for the BLA is <a href=\"https://seekingalpha.com/news/3190751-fda-accepts-roches-bla-ms-candidate-ocrelizumab-action-date-december-28\" target=\"_blank\">December 28</a>, announced in June. Opexa has not filed its marketing application yet. Top-line data from a Phase 2b study, Abili-T, are <a href=\"https://seekingalpha.com/news/3185549-opexa-28-percent-early-expectations-positive-tcelna-data-ms-study\" target=\"_blank\">expected in Q4</a>.</li>\n<li>An upcoming <a href=\"https://seekingalpha.com/news/2799056-roches-ocrelizumab-successful-late-stage-study-treatment-resistant-ms-fda-filing-tap-early\" target=\"_blank\">data presentation</a> may be the real reason for the bearish activity. On October 10, results from Roche's Phase 3 study, ORATORIO, will be presented at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Barcelona. The study involved patients with primary progressive MS. The study met its primary endpoint, a statistically valid reduction in the progression of clinical disability compared to placebo.</li>\n<li>The primary endpoint of Opexa's Abili-T is the percent change in brain volume at Month 24 measured by MRI. The indication is secondary progressive MS. If Roche's ocrelizumab is approved for primary progressive MS, it will be used to treat secondary progressive MS so Abili-T's top-line data need to be impressive.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3208809\" data-linked=\"Opexa longs head for the exits ahead of Roche data presentation for MS candidate ocrelizumab; shares down 22%\" data-tweet=\"$ACER $ACER $RHHBY - Opexa longs head for the exits ahead of Roche data presentation for MS candidate ocrelizumab; shares down 22% https://seekingalpha.com/news/3208809-opexa-longs-head-for-exits-ahead-of-roche-data-presentation-for-ms-candidate-ocrelizumab?source=tweet\" data-url=\"https://seekingalpha.com/news/3208809-opexa-longs-head-for-exits-ahead-of-roche-data-presentation-for-ms-candidate-ocrelizumab\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208810\" data-ts=\"1473881872\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WFC\" target=\"_blank\">WFC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208810-wsj-federal-prosecutors-probing-wells-fargo-over-sales-practices\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WSJ: Federal prosecutors probing Wells Fargo over sales practices</a></h4><ul><li>At the moment it's just a headline, but the news looks to have hit Wells Fargo (NYSE:<a href='https://seekingalpha.com/symbol/WFC' title='Wells Fargo & Co.'>WFC</a>) a bit in the last few minutes. Shares are&nbsp;<font color='red'>down 0.8%</font>&nbsp;after having been up&nbsp;<font color='green'>nearly 1%</font>&nbsp;earlier in the session.</li></ul><div class=\"tiny-share-widget\" data-id=\"3208810\" data-linked=\"WSJ: Federal prosecutors probing Wells Fargo over sales practices\" data-tweet=\"$WFC - WSJ: Federal prosecutors probing Wells Fargo over sales practices https://seekingalpha.com/news/3208810-wsj-federal-prosecutors-probing-wells-fargo-over-sales-practices?source=tweet\" data-url=\"https://seekingalpha.com/news/3208810-wsj-federal-prosecutors-probing-wells-fargo-over-sales-practices\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208806\" data-ts=\"1473880614\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208806-stocks-give-up-gains\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stocks give up gains</a></h4><ul><li>Up smartly earlier in the session, the Dow and S&amp;P have edged into the red in the last few minutes. The Nasdaq - aided by a&nbsp;<font color='green'>3.4% advance</font>&nbsp;for Apple - is barely holding onto what's left of its gain,&nbsp;<font color='green'>up 0.25%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3208806\" data-linked=\"Stocks give up gains\" data-tweet=\"Stocks give up gains https://seekingalpha.com/news/3208806-stocks-give-up-gains?source=tweet\" data-url=\"https://seekingalpha.com/news/3208806-stocks-give-up-gains\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208803\" data-ts=\"1473879644\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208803-technology-top-5-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ISNS' title='Image Sensing Systems, Inc.'>ISNS</a> <font color='green'>+11%</font>. FH <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/EXTR' title='Extreme Networks, Inc.'>EXTR</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/GIMO' title='Gigamon, Inc.'>GIMO</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/BV-OLD' title='Bazaarvoice'>BV-OLD</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ATEA' title='Astea International, Inc.'>OTC:ATEA</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/RFIL' title='RF Industries, Ltd.'>RFIL</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/SPWR' title='SunPower Corporation'>SPWR</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/CYRN' title='CYREN Ltd.'>CYRN</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/NEON' title='Neonode, Inc.'>NEON</a> <font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3208803\" data-linked=\"Technology - Top 5 Gainers / Losers as of 3:00 pm\" data-tweet=\"$ISNS $XSPA $EXTR - Technology - Top 5 Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3208803-technology-top-5-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3208803-technology-top-5-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208800\" data-ts=\"1473879174\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DK\" target=\"_blank\">DK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208800-delek-alon-usa-primed-to-merge-citi-upgrades-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Delek, Alon USA &quot;primed to merge&quot;; Citi upgrades to Buy</a></h4><ul>     <li>Delek US Holdings (<a href=\"https://seekingalpha.com/symbol/DK\" title=\"Delek US Holdings, Inc.\">DK</a> <font color=\"red\">-1.8%</font>) and Alon USA Energy (<a href=\"https://seekingalpha.com/symbol/ALJ\" title=\"Alon USA Energy, Inc.\">ALJ</a> <font color=\"red\">-0.1%</font>) are initiated with <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/16/09/8456479/citi-sees-delek-alon-usa-primed-to-merge\" target=\"_blank\">Buy ratings</a>, with respective $23.50 and $10 price targets, at Citigroup, which says a potential merger of the two companies seems increasingly likely and could unlock value.</li>     <li>DK already owns a 48% stake in ALJ and recently sold its retail assets to COPEC, raising sufficient funds to acquire the remaining 52% stake via cash, Citi says.</li>     <li>Besides the synergies in procurement of crude and marketing of products, the firm says the clearest synergy is $71M that ALJ outlined in EBITDA that could be dropped into DK\u2019s MLP, a value that alone represents 100% of ALJ\u2019s market cap.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3208800\" data-linked=\"Delek, Alon USA &quot;primed to merge&quot;; Citi upgrades to Buy\" data-tweet=\"$DK $DK $ALJ - Delek, Alon USA &quot;primed to merge&quot;; Citi upgrades to Buy https://seekingalpha.com/news/3208800-delek-alon-usa-primed-to-merge-citi-upgrades-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3208800-delek-alon-usa-primed-to-merge-citi-upgrades-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208792\" data-ts=\"1473877695\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWTR\" target=\"_blank\">TWTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208792-cantor-fitzgerald-considers-thursday-night-football-twitters-last-chance-to-spark-user-growth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cantor Fitzgerald considers Thursday Night Football Twitter&#39;s last chance to spark user growth</a></h4><ul>\n<li>While Twitter (<a href=\"https://seekingalpha.com/symbol/TWTR\" title=\"Twitter, Inc.\">TWTR</a> <font color=\"green\">+1.7%</font>) is trading up on the <a href=\"https://seekingalpha.com/news/3208707-twitter-launches-live-streaming-apps-apple-tv-amazon-fire-tv-xbox-one-shares-open-2-percent\" target=\"_blank\">extension</a> of live-streamed content housed on its platform to Apple TV, Amazon Fire TV, and Xbox One apps, analyst Youssef Squali <a href=\"http://blogs.barrons.com/techtraderdaily/2016/09/14/twitters-jets-v-bills-game-is-make-or-break-says-cantor/\" target=\"_blank\">sees</a> a critical moment for the company as it plans to stream its first NFL game tomorrow night. Ten subsequent Thursday night games are scheduled to stream live on Twitter over the course of the NFL season.</li>\n<li>Squali: \"This may be mgt\u2019s last opportunity to reignite growth in users, engagement and monetization; failure to do so is likely to embolden shareholders to pressure the board to evaluate alternatives to maximize value, incl. M&amp;A and taking the company private.\"</li>\n<li>\n<a href=\"https://www.thestreet.com/story/13729710/1/twitter-twtr-stock-up-cantor-fitzgerald-nfl-stream-is-make-or-break.html\" target=\"_blank\">Maintains</a> a Hold rating and $18 price target (current price $18.08).</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3208792\" data-linked=\"Cantor Fitzgerald considers Thursday Night Football Twitter&#39;s last chance to spark user growth\" data-tweet=\"$TWTR - Cantor Fitzgerald considers Thursday Night Football Twitter&#39;s last chance to spark user growth https://seekingalpha.com/news/3208792-cantor-fitzgerald-considers-thursday-night-football-twitters-last-chance-to-spark-user-growth?source=tweet\" data-url=\"https://seekingalpha.com/news/3208792-cantor-fitzgerald-considers-thursday-night-football-twitters-last-chance-to-spark-user-growth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208789\" data-ts=\"1473876088\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208789-energy-materials-top-5-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm</a></h4><ul> <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CC' title='The Chemours Company'>CC</a> <font color='green'>+6%</font>. TCK <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/MMLP' title='Martin Midstream Partners L.P.'>MMLP</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/CWEI' title='Clayton Williams Energy, Inc.'>CWEI</a> <font color='green'>+5%</font>.</li> <li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CIE' title='Cobalt International Energy, Inc.'>CIE</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/CRK' title='Comstock Resources Inc.'>CRK</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/PQ' title='PetroQuest Energy Inc.'>PQ</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/MXC' title='Mexco Energy Corporation'>MXC</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/SNMX' title='Senomyx, Inc.'>SNMX</a> <font color='red'>-7%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3208789\" data-linked=\"Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm\" data-tweet=\"$CC $TECK $MMLP - Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3208789-energy-materials-top-5-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3208789-energy-materials-top-5-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208787\" data-ts=\"1473875961\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GIMO\" target=\"_blank\">GIMO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208787-gigamonplus-7-william-blair-notes-positives\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gigamon +7%; William Blair notes positives</a></h4><ul>\n<li>Analyst Jason Adler <a href=\"http://www.streetinsider.com/Analyst+Comments/Gigamon%2C+Inc.+%28GIMO%29%3A+Notes+From+Management+Meetings+-+William+Blair/12030211.html\" target=\"_blank\">restates</a> an Outperform rating.</li>\n<li>Cites security department deal momentum, AWS visibility solution catalysts and strengthening market trust.</li>\n<li>Price target on Gigamon (<a href=\"https://seekingalpha.com/symbol/GIMO\" title=\"Gigamon, Inc.\">GIMO</a> <font color=\"green\">+7.3%</font>) not set.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3208787\" data-linked=\"Gigamon +7%; William Blair notes positives\" data-tweet=\"$GIMO - Gigamon +7%; William Blair notes positives https://seekingalpha.com/news/3208787-gigamonplus-7-william-blair-notes-positives?source=tweet\" data-url=\"https://seekingalpha.com/news/3208787-gigamonplus-7-william-blair-notes-positives\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208786\" data-ts=\"1473875847\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YUME\" target=\"_blank\">YUME</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208786-yume-up-6_2-after-getting-acquisition-interest-from-no-2-shareholder\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">YuMe up 6.2% after getting acquisition interest from No. 2 shareholder</a></h4><ul>   <li>In an SEC filing, YuMe (<a href=\"https://seekingalpha.com/symbol/YUME\" title=\"YuMe, Inc.\">YUME</a> <font color=\"green\">+6.2%</font>) confirms that it got an \"indication of interest\" in <a href=\"https://seekingalpha.com/filing/3224717\" target=\"_blank\">acquiring the company</a>, from its second-largest shareholder, AVI Partners.</li>    <li>The board has set a special committee of independent directors to examine the proposal, and it's in the process of choosing a financial adviser.</li>    <li>It's got \"no further comment\" on a possible deal.</li>    <li>\n<a href=\"https://seekingalpha.com/filing/3224696\" target=\"_blank\">Another filing today</a> notes that AVI Capital Yankee beneficially owns just over 3M shares, or 8.7% of the company; AVI Management holds about 8.8%; AVI Partners, 10.4%; James Dunn, 10.4%; Darren Wallis, 10.4%;</li> </ul><div class=\"tiny-share-widget\" data-id=\"3208786\" data-linked=\"YuMe up 6.2% after getting acquisition interest from No. 2 shareholder\" data-tweet=\"$YUME - YuMe up 6.2% after getting acquisition interest from No. 2 shareholder https://seekingalpha.com/news/3208786-yume-up-6_2-after-getting-acquisition-interest-from-no-2-shareholder?source=tweet\" data-url=\"https://seekingalpha.com/news/3208786-yume-up-6_2-after-getting-acquisition-interest-from-no-2-shareholder\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208779\" data-ts=\"1473873454\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VMEM\" target=\"_blank\">VMEM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208779-violin-memoryplus-10-releases-new-flash-arrays-amid-recent-share-dive\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Violin Memory +10%; releases new flash arrays amid recent share dive</a></h4><ul>\n<li>First news out of the company (<a href=\"https://seekingalpha.com/symbol/VMEM\" title=\"Violin Memory, Inc.\">VMEM</a> <font color=\"green\">+9.8%</font>) following its <a href=\"https://seekingalpha.com/news/3207976-violin-memory-minus-38-percent-following-highly-adverse-q2\" target=\"_blank\">negative Q2 report</a>, and this week's near <font color=\"red\">40% drop</font> in value, involves new <a href=\"http://www.violin-memory.com/products/flash-storage-platform-7650/\" target=\"_blank\">7650</a> and <a href=\"http://www.violin-memory.com/products/flash-storage-platform-7450/\" target=\"_blank\">7450</a> flash array products.</li>\n<li>President and CEO Kevin DeNuccio: \"Today, Violin Memory unveils the latest in a series of Violin Memory innovations that will fundamentally change the all flash array market, a market that Violin created ten years ago when it launched the industry's first all flash array. This launch is all about how IT professionals can be instrumental by leveraging storage technology to enable their companies to do great things, whether that be via private, public or hybrid cloud environments.\"</li>\n<li>Though it's encouraging to see the company releasing new products at a tough time for its stakeholders, some <a href=\"https://seekingalpha.com/article/4005153-violin-memory-end-near\" target=\"_blank\">consider</a> the time to continue building on this possibly running out.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3208779\" data-linked=\"Violin Memory +10%; releases new flash arrays amid recent share dive\" data-tweet=\"$VMEM - Violin Memory +10%; releases new flash arrays amid recent share dive https://seekingalpha.com/news/3208779-violin-memoryplus-10-releases-new-flash-arrays-amid-recent-share-dive?source=tweet\" data-url=\"https://seekingalpha.com/news/3208779-violin-memoryplus-10-releases-new-flash-arrays-amid-recent-share-dive\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208775\" data-ts=\"1473872482\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLNT\" target=\"_blank\">FLNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208775-analytics-firm-idi-renaming-cogint-moving-to-nasdaq-from-nyse\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analytics firm IDI renaming itself Cogint, moving to Nasdaq from NYSE</a></h4><ul>   <li>Analytics firm IDI (<a href=\"https://seekingalpha.com/symbol/IDI\" target=\"_blank\">IDI</a> <font color='green'>+3.1%</font>) is becoming Cogint, and will relist itself on Nasdaq under a new ticker.</li>    <li>In an <a href=\"https://seekingalpha.com/filing/3224702\" target=\"_blank\">SEC filing</a>, the company says it will delist from the NYSE effective with the close on Sept. 23.</li>    <li>It expects to reappear on Nasdaq Monday, Sept. 26, under the symbol COGT and new CUSIP number \"19241Q 101.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3208775\" data-linked=\"Analytics firm IDI renaming itself Cogint, moving to Nasdaq from NYSE\" data-tweet=\"$FLNT - Analytics firm IDI renaming itself Cogint, moving to Nasdaq from NYSE https://seekingalpha.com/news/3208775-analytics-firm-idi-renaming-cogint-moving-to-nasdaq-from-nyse?source=tweet\" data-url=\"https://seekingalpha.com/news/3208775-analytics-firm-idi-renaming-cogint-moving-to-nasdaq-from-nyse\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208771\" data-ts=\"1473871839\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARLZ-OLD\" target=\"_blank\">ARLZ-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208771-fda-action-date-today-for-aralez-pharmas-resubmitted-yosprala-marketing-application-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA action date today for Aralez Pharma&#39;s resubmitted Yosprala marketing application; shares down 9%</a></h4><ul>\n<li>Today is the FDA's PDUFA date for Aralez Pharmaceuticals' (<a href=\"https://seekingalpha.com/symbol/ARLZ-OLD\" title=\"Aralez Pharmaceuticals Inc.\">ARLZ-OLD</a> <font color=\"red\">-8.5%</font>) resubmitted New Drug Application (NDA) seeking approval of YOSPRALA (aspirin + omeprazole) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers.</li>\n<li>The company received two earlier Complete Response Letters (CRLs), one in December 2014 and an earlier one in April 2014. The deficiencies pertained to the manufacturing facility of the then-aspirin supplier. The resubmission includes a new primary aspirin supplier in addition to an alternative supplier.</li>\n<li>\n<a href=\"http://aralez.com/Portfolio/yosprala/\" target=\"_blank\">YOSPRALA </a>is a combination of <a href=\"http://www.drugs.com/omeprazole.html\" target=\"_blank\">omeprazole</a>, a proton pump inhibitor that reduces stomach acid, and a PH-sensitive enteric coated aspirin.</li>\n<li>Investors don't appear optimistic. Shares are down on 4x higher volume.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3169689-fda-accepts-aralez-pharmas-resubmitted-nda-yosprala-shares-16-percent-premarket\" target=\"_blank\">FDA accepts Aralez Pharma's resubmitted NDA for YOSPRALA; shares up 16% premarket</a> (March 28)</li>\n<li>\n<strong>Update</strong>: On September 15, the company announced that the FDA approved YOSPRALA.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3208771\" data-linked=\"FDA action date today for Aralez Pharma&#39;s resubmitted Yosprala marketing application; shares down 9%\" data-tweet=\"$ARLZ-OLD - FDA action date today for Aralez Pharma&#39;s resubmitted Yosprala marketing application; shares down 9% https://seekingalpha.com/news/3208771-fda-action-date-today-for-aralez-pharmas-resubmitted-yosprala-marketing-application-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3208771-fda-action-date-today-for-aralez-pharmas-resubmitted-yosprala-marketing-application-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>46&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208770\" data-ts=\"1473871641\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208770-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/VTAE' title='Vitae Pharmaceuticals'>VTAE</a> <font color='green'>+158%</font>. <a href='https://seekingalpha.com/symbol/BSPM' title='Biostar Pharmaceutic'>OTC:BSPM</a> <font color='green'>+76%</font>. <a href='https://seekingalpha.com/symbol/ACST' title='Acasti Pharma, Inc.'>ACST</a> <font color='green'>+34%</font>. <a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/ABAC-OLD' title='Renmin Tianli Group'>ABAC-OLD</a> <font color='green'>+20%</font>. STEM <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/MHGC' title='Morgans Hotel Group Co.'>MHGC</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/RLH' title='Red Lion Hotels Corporation'>RLH</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/GBT' title='Global Blood Therapeutics'>GBT</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/ZAIS' title='ZAIS Group Holdings'>ZAIS</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/LFVN' title='LifeVantage Corporation'>LFVN</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/RFIL' title='RF Industries, Ltd.'>RFIL</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/RLGT' title='Radiant Logistics, Inc.'>RLGT</a> <font color='red'>-15%</font>. APPY <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/EDUC' title='Educational Development Corporation'>EDUC</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/CLRB' title='Cellectar Biosciences, Inc.'>CLRB</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/SPWR' title='SunPower Corporation'>SPWR</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/VIVE' title='Viveve Medical, Inc.'>VIVE</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/SALT' title='Scorpio Bulkers Inc'>SALT</a> <font color='red'>-10%</font>. NVGN <font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3208770\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$VTAE $BSPM $ACST - Midday Gainers / Losers https://seekingalpha.com/news/3208770-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3208770-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208767\" data-ts=\"1473870935\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPPI\" target=\"_blank\">SPPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208767-ad-comm-thumbs-down-on-spectrums-apaziquone-shares-off-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ad Comm thumbs down on Spectrum&#39;s apaziquone; shares off 4%</a></h4><ul><li>The FDA's Oncologic Drugs Advisory Committee votes 14 - 0 against approving Spectrum Pharmaceuticals' (<a href=\"https://seekingalpha.com/symbol/SPPI\" title=\"Spectrum Pharmaceuticals, Inc.\">SPPI</a> <font color=\"red\">-3.6%</font>) apaziquone NDA for bladder cancer.</li></ul><div class=\"tiny-share-widget\" data-id=\"3208767\" data-linked=\"Ad Comm thumbs down on Spectrum&#39;s apaziquone; shares off 4%\" data-tweet=\"$SPPI - Ad Comm thumbs down on Spectrum&#39;s apaziquone; shares off 4% https://seekingalpha.com/news/3208767-ad-comm-thumbs-down-on-spectrums-apaziquone-shares-off-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3208767-ad-comm-thumbs-down-on-spectrums-apaziquone-shares-off-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208763\" data-ts=\"1473868898\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208763-comsumer-goods-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Comsumer Goods - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li>\n<b>Gainers:</b> <a href=\"https://seekingalpha.com/symbol/ABAC-OLD\" title=\"Renmin Tianli Group\">ABAC-OLD</a> <font color=\"green\">+14%</font>. <a href=\"https://seekingalpha.com/symbol/DFBG-OLD\" title=\"Differential Brands Group Inc.\">DFBG-OLD</a> <font color=\"green\">+7%</font>. <a href=\"https://seekingalpha.com/symbol/TSE\" title=\"Trinseo S.A.\">TSE</a> <font color=\"green\">+6%</font>. <a href=\"https://seekingalpha.com/symbol/ACAT\" title=\"Arctic Cat Inc.\">ACAT</a> <font color=\"green\">+5%</font>.</li>\n<li>\n<b>Losers:</b> <a href=\"https://seekingalpha.com/symbol/LFVN\" title=\"LifeVantage Corporation\">LFVN</a> <font color=\"red\">-20%</font>. <a href=\"https://seekingalpha.com/symbol/PME\" title=\"Pingtan Marine Enterprise Ltd.\">PME</a> <font color=\"red\">-6%</font>. <a href=\"https://seekingalpha.com/symbol/EVK\" title=\"Ever-Glory International Group, Inc\">EVK</a> <font color=\"red\">-6%</font>.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3208763\" data-linked=\"Comsumer Goods - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$ABAC-OLD $DFBG-OLD $TSE - Comsumer Goods - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3208763-comsumer-goods-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3208763-comsumer-goods-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208760\" data-ts=\"1473868674\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EGO\" target=\"_blank\">EGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208760-eldorado-gold-gets-two-notch-boost-bofa-merrill\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eldorado Gold gets two-notch boost at BofA Merrill</a></h4><ul>     <li>Eldorado Gold (<a href=\"https://seekingalpha.com/symbol/EGO\" title=\"Eldorado Gold Corporation\">EGO</a> <font color=\"green\">+1.6%</font>) is <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/16/09/8457242/bank-of-america-does-a-double-upgrade-on-eldorado-gold-e\" target=\"_blank\">upgraded to Buy</a> from Underperform with a $5 price target at BofA Merrill Lynch, believing that as EGO advances its two Greek projects to the production stage, the stock's sizable discount to its peer producers will contract.</li>     <li>The firm also notes that the EGO's production levels were higher and operating costs lower than estimates, and the company guided to gold output of more than 900K oz. by 2020, more than double expected 2017 levels.</li>     <li>BofA adds that the sale of the Chinese gold mines should greatly strengthen EGO\u2019s balance sheet, providing sufficient liquidity to advance the projects.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3208760\" data-linked=\"Eldorado Gold gets two-notch boost at BofA Merrill\" data-tweet=\"$EGO - Eldorado Gold gets two-notch boost at BofA Merrill https://seekingalpha.com/news/3208760-eldorado-gold-gets-two-notch-boost-bofa-merrill?source=tweet\" data-url=\"https://seekingalpha.com/news/3208760-eldorado-gold-gets-two-notch-boost-bofa-merrill\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208755\" data-ts=\"1473868183\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BSPM\" target=\"_blank\">BSPM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208755-biostar-short-sellers-run-for-hills-shares-up-64\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biostar short sellers run for the hills; shares up 64%</a></h4><ul>\n<li>Thinly traded nano cap Biostar Pharmaceuticals (<a href=\"https://seekingalpha.com/symbol/BSPM\" title=\"Biostar Pharmaceutic\">OTC:BSPM</a> <font color=\"green\">+63.9%</font>) powers ahead on no particular news other than the dead bodies of short sellers.</li>\n<li>The China-based firm develops and markets drugs and health supplements to treat a range of diseases. According to the company, its top seller is an OTC medicine called Xin Ao Xing Oleanolic Acid Capsule for the treatment of chronic hepatitis B virus infection. It currently makes 22 products and one medical device. In Q2 it booked $600K in sales, down 95.6% yoy.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3208755\" data-linked=\"Biostar short sellers run for the hills; shares up 64%\" data-tweet=\"$BSPM - Biostar short sellers run for the hills; shares up 64% https://seekingalpha.com/news/3208755-biostar-short-sellers-run-for-hills-shares-up-64?source=tweet\" data-url=\"https://seekingalpha.com/news/3208755-biostar-short-sellers-run-for-hills-shares-up-64\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208757\" data-ts=\"1473868150\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MHGC\" target=\"_blank\">MHGC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208757-morgans-hotel-group-spikes-after-new-buyout-offer-arrives\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgans Hotel Group spikes after new buyout offer arrives</a></h4><ul>     <li>Morgans Hotel Group (<a href='https://seekingalpha.com/symbol/MHGC' title='Morgans Hotel Group Co.'>MHGC</a> <font color='green'>+21.5%</font>) spikes after the company receives a new takeover offer from \"Bidder V\" at $2.75 per share.</li>     <li>The company is holding a special meeting to evaluate the offer from Bidder V.</li>           </ul><div class=\"tiny-share-widget\" data-id=\"3208757\" data-linked=\"Morgans Hotel Group spikes after new buyout offer arrives\" data-tweet=\"$MHGC - Morgans Hotel Group spikes after new buyout offer arrives https://seekingalpha.com/news/3208757-morgans-hotel-group-spikes-after-new-buyout-offer-arrives?source=tweet\" data-url=\"https://seekingalpha.com/news/3208757-morgans-hotel-group-spikes-after-new-buyout-offer-arrives\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208756\" data-ts=\"1473868034\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208756-peso-tanks-trump-takes-lead\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Peso tanks as Trump takes lead</a></h4><ul>\n<li>A new Bloomberg poll <a href=\"http://blogs.barrons.com/emergingmarketsdaily/2016/09/14/ohio-likes-trump-mexico-peso-dumped/?mod=BOL_hp_blog_em\" target=\"_blank\">gives Donald Trump a</a> five percentage point lead in Ohio - a state which has a strong tendency to pick winners in U.S. presidential elections.</li>\n<li>The peso <font color=\"red\">dipped 0.7%</font> against the dollar on the news. It's now down 10% vs. the greenback this year, and the weakest emerging market currency in Q3.</li>\n<li>The iShares Mexico ETF (<a href=\"https://seekingalpha.com/symbol/EWW\" title=\"iShares MSCI Mexico Capped ETF\">EWW</a> <font color=\"red\">-1.3%</font>).</li>\n<li>ETFs: <a href=\"https://seekingalpha.com/symbol/EWW\" title=\"iShares MSCI Mexico Capped ETF\">EWW</a>, <a href=\"https://seekingalpha.com/symbol/MXF\" title=\"Mexico Fund\">MXF</a>, <a href=\"https://seekingalpha.com/symbol/MXE\" title=\"Mexico Equity&amp;Income Fund\">MXE</a>, <a href=\"https://seekingalpha.com/symbol/UMX\" title=\"ProShares Ultra MSCI Mexico Capped IMI ETF\">UMX</a>, <a href=\"https://seekingalpha.com/symbol/DBMX\" title=\"Deutsche X-trackers MSCI Mexico Hedged Equity ETF\">DBMX</a>, <a href=\"https://seekingalpha.com/symbol/SMK\" title=\"ProShares UltraShort MSCI Mexico Capped IMI ETF\">SMK</a>, <a href=\"https://seekingalpha.com/symbol/QMEX\" title=\"SPDR MSCI Mexico Quality Mix ETF\">QMEX</a>, <a href=\"https://seekingalpha.com/symbol/HEWW\" title=\"iShares Currency Hedged MSCI Mexico ETF\">HEWW</a>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3208756\" data-linked=\"Peso tanks as Trump takes lead\" data-tweet=\"$EWW $MXF $MXE - Peso tanks as Trump takes lead https://seekingalpha.com/news/3208756-peso-tanks-trump-takes-lead?source=tweet\" data-url=\"https://seekingalpha.com/news/3208756-peso-tanks-trump-takes-lead\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208718\" data-ts=\"1473867918\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208718-healthcare-top-5-gainers-losers-of-11-45\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:45 am</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/VTAE' title='Vitae Pharmaceuticals'>VTAE</a> <font color='green'>+158%</font>. <a href='https://seekingalpha.com/symbol/BSPM' title='Biostar Pharmaceutic'>OTC:BSPM</a> <font color='green'>+67%</font>. <a href='https://seekingalpha.com/symbol/ACST' title='Acasti Pharma, Inc.'>ACST</a> <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a> <font color='green'>+25%</font>. STEM <font color='green'>+21%</font>.</li><li><b>Losers:</b> APPY <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/VIVE' title='Viveve Medical, Inc.'>VIVE</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/NYMX' title='Nymox Pharmaceutical Corporation'>NYMX</a> <font color='red'>-10%</font>. NVGN <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/MDGS' title='Medigus Ltd'>MDGS</a> <font color='red'>-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3208718\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:45 am\" data-tweet=\"$VTAE $BSPM $ACST - Healthcare - Top 5 Gainers / Losers as of 11:45 am https://seekingalpha.com/news/3208718-healthcare-top-5-gainers-losers-of-11-45?source=tweet\" data-url=\"https://seekingalpha.com/news/3208718-healthcare-top-5-gainers-losers-of-11-45\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208742\" data-ts=\"1473864971\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCX\" target=\"_blank\">FCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208742-freeport-mcmoran-downgraded-morgan-stanley-on-copper-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Freeport McMoRan downgraded at Morgan Stanley on copper outlook</a></h4><ul>     <li>Freeport McMoRan (<a href=\"https://seekingalpha.com/symbol/FCX\" title=\"Freeport-McMoRan Inc.\">FCX</a> <font color=\"red\">-3.1%</font>) is <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/16/09/8456352/morgan-stanley-downgrades-freeport-mcmoran-on-valuation-\" target=\"_blank\">downgraded</a> to Underweight from Equal Weight with a $7 price target, cut from $9, at Morgan Stanley, which says the risk/reward balance now is skewed to the downside as the stock is now pricing in $2.75/lb copper, above the firm's expected $2.43 average over the next three years.</li>     <li>\u201cCopper would need to rise closer to the $3/lb mark for the company to be able to continue to both de-lever and pursue necessary mine extension capex at Grasberg,\" Stanley's Evan Kurtz writes.</li>     <li>FCX is in negotiations with Indonesia's government for the sale of its 10.64% stake in the Grasberg copper asset, for which FCX is seeking $1.7B while the government believes the stake is worth only $630M; Kurtz values the stake at $1.25B, near the midpoint of the current bid-ask.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3208742\" data-linked=\"Freeport McMoRan downgraded at Morgan Stanley on copper outlook\" data-tweet=\"$FCX - Freeport McMoRan downgraded at Morgan Stanley on copper outlook https://seekingalpha.com/news/3208742-freeport-mcmoran-downgraded-morgan-stanley-on-copper-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3208742-freeport-mcmoran-downgraded-morgan-stanley-on-copper-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208725\" data-ts=\"1473863900\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AST\" target=\"_blank\">AST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208725-asterias-bio-reports-encouraging-interim-results-in-early-stage-study-of-ast-opc1-cells-in\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Asterias Bio reports encouraging interim results in early-stage study of AST-OPC1 cells in spinal cord injury; shares up 6%</a></h4><ul>\n<li>Thinly traded micro cap Asterias Biotherapeutics (<a href=\"https://seekingalpha.com/symbol/AST\" title=\"Asterias Biotherapeutics, Inc.\">AST</a> <font color=\"green\">+6.3%</font>) perks up on increased volume in response to its <a href=\"http://www.prnewswire.com/news-releases/asterias-biotherapeutics-announces-positive-efficacy-data-in-patients-with-complete-cervical-spinal-cord-injuries-treated-with-ast-opc1-300327628.html\" target=\"_blank\">announcement </a>of positive preliminary data from its Phase 1/2a study, SCiSTAR, assessing its AST-OPC1 (oligodendrocyte progenitor) cells for the treatment of complete cervical spinal cord injury. The data were presented at the 55th Annual Scientific Meeting of the International Spinal Cord Society in Vienna, Austria.</li>\n<li>All five patients treated with 10M cells showed improved upper extremity scores compared to baseline. At Day 90 of follow-up, four of four patients improved one motor level on at least one side while two of four improved two motor levels on at least one side. One patient improved two levels on both sides. Existing research suggests patients with at least a two-level improvement may regain the ability to perform daily activities such as feeding, dressing and bathing.</li>\n<li>In patients treated with 2M cells, three of three showed improved upper extremity scores versus baseline. At Year 1 of follow-up, one patient improved one motor level on one side and two have improved one motor level on both sides.</li>\n<li>The company expects to report the efficacy of 20M cells in 2017.</li>\n<li>\n<a href=\"https://clinicaltrials.gov/ct2/show/NCT02302157?term=scistar&amp;rank=1\" target=\"_blank\">SCiSTAR </a>is an open-label, single-arm study assessing escalating doses of up to 20M AST-OPC1 cells in up to 35 patients with sub-acute C-5 to C-7 complete cervical spinal cord injury. These individuals have lost all motor and sensory function below the injury site.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3192687-asterias-bio-completes-enrollment-first-efficacy-cohort-early-stage-study-ast-opc1-spinal\" target=\"_blank\">Asterias Bio completes enrollment in first efficacy cohort in early-stage study of AST-OPC1 in spinal cord injury</a> (July 12)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3208725\" data-linked=\"Asterias Bio reports encouraging interim results in early-stage study of AST-OPC1 cells in spinal cord injury; shares up 6%\" data-tweet=\"$AST - Asterias Bio reports encouraging interim results in early-stage study of AST-OPC1 cells in spinal cord injury; shares up 6% https://seekingalpha.com/news/3208725-asterias-bio-reports-encouraging-interim-results-in-early-stage-study-of-ast-opc1-cells-in?source=tweet\" data-url=\"https://seekingalpha.com/news/3208725-asterias-bio-reports-encouraging-interim-results-in-early-stage-study-of-ast-opc1-cells-in\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208732\" data-ts=\"1473863556\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ESI-OLD\" target=\"_blank\">ESI-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208732-itt-students-start-debt-strike\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ITT students start debt strike</a></h4><ul> <li>Former students at ITT Technical Institutes are launching a <a href=\"http://www.bloomberg.com/news/articles/2016-09-14/more-than-100-former-itt-tech-students-launch-debt-strike-against-department-of-education\" target=\"_blank\">debt strike</a> after ending up with what they call worthless academic credentials from the various ITT schools.</li> <li>Last week, the Department of Education banned new students at ITT from using federal student aid.</li> <li>The debt strike isn't a surprise to those who have been warning about a student loan bubble.</li> <li>Shares of ITT Educational Service (NYSE:<a href=\"https://seekingalpha.com/symbol/ESI-OLD\" title=\"ITT Educational Services Inc.\">ESI-OLD</a>) are down 90% in the last year amid the unraveling of the company's model.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3208732\" data-linked=\"ITT students start debt strike\" data-tweet=\"$ESI-OLD - ITT students start debt strike https://seekingalpha.com/news/3208732-itt-students-start-debt-strike?source=tweet\" data-url=\"https://seekingalpha.com/news/3208732-itt-students-start-debt-strike\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208730\" data-ts=\"1473863529\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208730-apple-shares-continue-torrid-run-up-headlines-shift-from-tax-complications-to-new-products\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple shares continue torrid run-up as headlines shift from tax complications to new products</a></h4><ul>\n<li>Apple (<a href=\"https://seekingalpha.com/symbol/AAPL\" title=\"Apple Inc.\">AAPL</a> <font color=\"green\">+3.1%</font>) is trading <font color=\"green\">up 8%</font> since last Friday and is realizing the highest share price levels it's seen in five months.</li>\n<li>While the company's <a href=\"https://seekingalpha.com/news/3206153-tim-cook-berates-european-commission-message-european-community\" target=\"_blank\">Irish tax complications</a> took focus at the end of August, favorable <a href=\"https://seekingalpha.com/news/3208435-apple-plus-3-percent-carrier-iphone-7-pre-orders-encouraging\" target=\"_blank\">iPhone 7 demand</a> along with the release of <a href=\"https://seekingalpha.com/news/3207447-apple-details-watch-series-2\" target=\"_blank\">Watch Series 2</a> and other developments <a href=\"http://www.apple.com/apple-events/september-2016/\" target=\"_blank\">disclosed</a> at the company's event last week have left the matter sidelined as investors look toward the future.</li>\n<li>Further tailwinds from Samsung's Galaxy Note 7 <a href=\"https://seekingalpha.com/news/3208498-samsung-planning-software-update-limit-galaxy-note-7-battery-charge-capacity\" target=\"_blank\">misfortune</a> have also marked a favorably timed gift.</li>\n<li>With the recent share move, Apple is now <font color=\"red\">off around 3.5%</font> on the year and <font color=\"green\">up around 14%</font> over the last three months.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3208730\" data-linked=\"Apple shares continue torrid run-up as headlines shift from tax complications to new products\" data-tweet=\"$AAPL - Apple shares continue torrid run-up as headlines shift from tax complications to new products https://seekingalpha.com/news/3208730-apple-shares-continue-torrid-run-up-headlines-shift-from-tax-complications-to-new-products?source=tweet\" data-url=\"https://seekingalpha.com/news/3208730-apple-shares-continue-torrid-run-up-headlines-shift-from-tax-complications-to-new-products\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>83&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208727\" data-ts=\"1473862842\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208727-stocks-back-on-rise-boosted-apple-and-lower-rates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stocks back on the rise, boosted by Apple and lower rates</a></h4><ul><li>After opening flat, stocks have turned higher in mid-morning action, with the Nasdaq's&nbsp;<font color='green'>0.65% advance</font>&nbsp;leading the way. Helping the Nasdaq, is the continuation of a big move for Apple, which is&nbsp;<font color='green'>up 3.3%</font>&nbsp;today.</li><li>The S&amp;P 500 is&nbsp;<font color='green'>ahead 0.35%</font>, and the Dow&nbsp;<font color='green'>0.25%</font>&nbsp;as interest rate relax a bit - the 10-year Treasury yield is down 4.5 basis points to 1.68%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3208727\" data-linked=\"Stocks back on the rise, boosted by Apple and lower rates\" data-tweet=\"Stocks back on the rise, boosted by Apple and lower rates https://seekingalpha.com/news/3208727-stocks-back-on-rise-boosted-apple-and-lower-rates?source=tweet\" data-url=\"https://seekingalpha.com/news/3208727-stocks-back-on-rise-boosted-apple-and-lower-rates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208716\" data-ts=\"1473860989\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VISN\" target=\"_blank\">VISN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208716-visionchina-media-closes-sale-of-subway-mobile-tv-ad-business\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VisionChina Media closes sale of subway mobile TV ad business</a></h4><ul>   <li>VisionChina Media (<a href=\"https://seekingalpha.com/symbol/VISN\" title=\"VisionChina Media, Inc.\">VISN</a> <font color=\"green\">+3.6%</font>) has closed on the sale of a minority stake in its subway mobile TV ad business.</li>    <li>The company's wrapped a transaction selling 49% of VisionChina New Culture Media Co. to Ledman Optoelectronic, terms they had agreed to in August.</li>    <li>VisionChina says it's \"open in the future\" to selling the remaining 51% position. It had <a href=\"https://seekingalpha.com/news/3111756\" target=\"_blank\">struck a $119M deal</a> to sell the entire business to Ledman in February before Ledman pushed to suspend the (later terminated) deal.</li>    <li>The company has gotten 61M yuan (about $9.1M) in cash and 321.2M yuan (about $48.1M) in the form of Ledman shares. VisionChina Media indirectly owns 4.88% of Ledman, in shares that are subject to lock-up until May 31, 2019.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3208716\" data-linked=\"VisionChina Media closes sale of subway mobile TV ad business\" data-tweet=\"$VISN - VisionChina Media closes sale of subway mobile TV ad business https://seekingalpha.com/news/3208716-visionchina-media-closes-sale-of-subway-mobile-tv-ad-business?source=tweet\" data-url=\"https://seekingalpha.com/news/3208716-visionchina-media-closes-sale-of-subway-mobile-tv-ad-business\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208707\" data-ts=\"1473859998\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWTR\" target=\"_blank\">TWTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208707-twitter-launches-live-streaming-apps-for-apple-tv-amazon-fire-tv-and-xbox-one-shares-open-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Twitter launches live-streaming apps for Apple TV, Amazon Fire TV, and Xbox One; shares open 2% higher</a></h4><ul>\n<li>All live-streamed video on Twitter's (<a href=\"https://seekingalpha.com/symbol/TWTR\" title=\"Twitter, Inc.\">TWTR</a> <font color=\"green\">+2.1%</font>) platform will be available within the apps.</li>\n<li>Highlights include 10 <a href=\"https://seekingalpha.com/news/3203199-twitter-looks-launch-apple-tv-app\" target=\"_blank\">NFL Thursday Night Football games</a>, <a href=\"https://seekingalpha.com/news/3195442-twitter-live-stream-select-market-mlb-nhl-games\" target=\"_blank\">MLB Advanced Media content</a>, <a href=\"https://seekingalpha.com/news/3193972-twitter-signs-nba-deal-stream-new-shows\" target=\"_blank\">NBA content</a> and <a href=\"https://seekingalpha.com/news/3193287-twitter-pacminus-12-networks-partner\" target=\"_blank\">Pac 12 Networks games</a>, along with other media.</li>\n<li>CFO Anthony Noto: \"These devices will bring Twitter's live streaming video experience to life on the TV screen. Twitter has always been a great complement to TV, and now fans can enjoy even more premium video with live Tweets \u2014 and the best content on Twitter \u2014 right from their TVs. We're excited to introduce this new experience to people, without requiring a paywall or having to log in to Twitter.\"</li>\n<li>While the most substantial news from the company of late involves content partnerships and live-video initiatives, this development continues to align with a direction it has remained committed to.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3208707\" data-linked=\"Twitter launches live-streaming apps for Apple TV, Amazon Fire TV, and Xbox One; shares open 2% higher\" data-tweet=\"$TWTR - Twitter launches live-streaming apps for Apple TV, Amazon Fire TV, and Xbox One; shares open 2% higher https://seekingalpha.com/news/3208707-twitter-launches-live-streaming-apps-for-apple-tv-amazon-fire-tv-and-xbox-one-shares-open-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3208707-twitter-launches-live-streaming-apps-for-apple-tv-amazon-fire-tv-and-xbox-one-shares-open-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208705\" data-ts=\"1473859319\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208705-premarket-gainers-losers-of-9-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers / Losers as of 9:10 am</a></h4><ul> <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/VTAE' title='Vitae Pharmaceuticals'>VTAE</a> <font color='green'>+157%</font>. <a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/BLFS' title='BioLife Solutions, Inc.'>BLFS</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/OPTT' title='Ocean Power Technologies, Inc.'>OPTT</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/AST' title='Asterias Biotherapeutics, Inc.'>AST</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/HOME' title='At Home Group'>HOME</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/PLUG' title='Plug Power, Inc.'>PLUG</a> <font color='green'>+7%</font>.</li> <li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/OAS' title='Oasis Petroleum Inc.'>OAS</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/ATW' title='Atwood Oceanics Inc.'>ATW</a> <font color='red'>-5%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3208705\" data-linked=\"Premarket Gainers / Losers as of 9:10 am\" data-tweet=\"$VTAE $SRPT $BLFS - Premarket Gainers / Losers as of 9:10 am https://seekingalpha.com/news/3208705-premarket-gainers-losers-of-9-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3208705-premarket-gainers-losers-of-9-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208702\" data-ts=\"1473859064\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NUE\" target=\"_blank\">NUE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208702-nucor-offers-below-consensus-q3-earnings-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nucor offers below-consensus Q3 earnings guidance</a></h4><ul>\n<li>Nucor (NYSE:<a href=\"https://seekingalpha.com/symbol/NUE\" title=\"Nucor Corporation\">NUE</a>) <font color=\"red\">-2.2%</font> premarket after saying it expects Q3 EPS of $0.85-$0.90, better than the $0.71 in the year-ago quarter but below the analyst consensus estimate of $0.95.</li>\n<li>NUE says flat-rolled trade cases are having a positive impact, as steel imports are  down in the first seven months of the year vs. the same period last  year and duties are in place and being collected.</li>\n<li>NUE expects profitability of its sheet mills to improve due to higher average  selling prices, which benefited in part from contract sales that are priced on a lagging quarterly  basis; demand for cold-rolled and galvanized sheet products is robust, but  demand for hot-rolled sheet products has weakened since H1.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3208702\" data-linked=\"Nucor offers below-consensus Q3 earnings guidance\" data-tweet=\"$NUE - Nucor offers below-consensus Q3 earnings guidance https://seekingalpha.com/news/3208702-nucor-offers-below-consensus-q3-earnings-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3208702-nucor-offers-below-consensus-q3-earnings-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208701\" data-ts=\"1473859013\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LFVN\" target=\"_blank\">LFVN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208701-lifevantage-delays-release-of-q4-and-fiscal-year-results-reviews-international-sales-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LifeVantage delays release of Q4 and fiscal year results as it reviews international sales; shares down 25% premarket</a></h4><ul><li>Thinly traded micro cap LifeVantage (NASDAQ:<a href=\"https://seekingalpha.com/symbol/LFVN\" title=\"LifeVantage Corporation\">LFVN</a>) slumps <font color=\"red\">25%</font> premarket on light volume in response to its announcement that it will delay the release of its Q4 and fiscal 2016 results so it can review its sales in certain international markets. It says it is unable to estimate the impact of the review on its net revenue, tax expense, net income or other line items until the process is completed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3208701\" data-linked=\"LifeVantage delays release of Q4 and fiscal year results as it reviews international sales; shares down 25% premarket\" data-tweet=\"$LFVN - LifeVantage delays release of Q4 and fiscal year results as it reviews international sales; shares down 25% premarket https://seekingalpha.com/news/3208701-lifevantage-delays-release-of-q4-and-fiscal-year-results-reviews-international-sales-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3208701-lifevantage-delays-release-of-q4-and-fiscal-year-results-reviews-international-sales-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208699\" data-ts=\"1473858695\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LVS\" target=\"_blank\">LVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208699-parisian-is-talk-of-macau\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">The Parisian is the talk of Macau</a></h4><ul> <li>All eyes in Macau were on the grand opening of the $2.7B Parisian Macao yesterday. The 3K-room casino complex is the fifth property owned by Las Vegas Sands in Macau.</li> <li>A huge fireworks show and considerable fanfare marked the occasion which arrived at what many analysts see as a turning point for the gambling mecca.</li> <li>\"We conclude that Macau is now at the start of a mass-led GGR (gross gaming revenue) recovery. Importantly, both base mass and premium mass are growing again,\u201d says Deutsche Bank analyst Karen Tang.</li> <li>Citi had a <a href=\"http://blogs.barrons.com/emergingmarketsdaily/2016/09/13/bienvenue-baccarat-is-sands-new-macau-casino-a-high-roller-magnet/\" target=\"_blank\">team</a> in place at the opening to dive into some bet counting. \"Our quick table survey showed that there were 212 opened baccarat tables at the Grind Mass area. Average minimum bet was HK$953 (with ~76% of the tables priced at HK$1,000). At the Ruby Room, its high-limit area, there were 22 baccarat tables with an average minimum bet of HK$2,591,\" tabulates the Citi team.</li> <li>On Wall Street, Argus <a href=\"https://twitter.com/Briefingcom/status/776016291429703680\" target=\"_blank\">upgrades</a> Las Vegas Sands (NYSE:<a href=\"https://seekingalpha.com/symbol/LVS\" title=\"Las Vegas Sands Corp.\">LVS</a>) to a Buy rating.</li> <li>LVS <font color=\"green\">+1.24%</font> premarket to $57.24.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3208699\" data-linked=\"The Parisian is the talk of Macau\" data-tweet=\"$LVS - The Parisian is the talk of Macau https://seekingalpha.com/news/3208699-parisian-is-talk-of-macau?source=tweet\" data-url=\"https://seekingalpha.com/news/3208699-parisian-is-talk-of-macau\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208694\" data-ts=\"1473858301\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLUU\" target=\"_blank\">GLUU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208694-glu-mobile-acquires-community-driven-poke-radar\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Glu Mobile acquires community-driven &#39;Poke Radar&#39;</a></h4><ul>   <li>Glu Mobile (NASDAQ:<a href=\"https://seekingalpha.com/symbol/GLUU\" title=\"Glu Mobile Inc.\">GLUU</a>) is <font color=\"green\">up 2.2%</font> premarket following news that it's acquired Poke Radar, a quickly built community add-on to the hit game <i>Pokemon Go.</i>\n</li>    <li>Glu is paying $500K in cash for all assets associated with the free application, which uses user-submitted information to help players locate sought-after creatures in the game.</li>    <li>The <i>Poke Radar</i> team will continue its work at Glu. The app is a \"unique property which was built swiftly and in a nimble manner,\" says Glu CEO Niccolo de Masi. \"I look forward to the significant contributions we expect this team to make at Glu.\u201d</li> </ul><div class=\"tiny-share-widget\" data-id=\"3208694\" data-linked=\"Glu Mobile acquires community-driven &#39;Poke Radar&#39;\" data-tweet=\"$GLUU - Glu Mobile acquires community-driven &#39;Poke Radar&#39; https://seekingalpha.com/news/3208694-glu-mobile-acquires-community-driven-poke-radar?source=tweet\" data-url=\"https://seekingalpha.com/news/3208694-glu-mobile-acquires-community-driven-poke-radar\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208693\" data-ts=\"1473858249\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGIO\" target=\"_blank\">AGIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208693-agios-pharma-launches-equity-offering-shares-down-5-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Agios Pharma launches equity offering; shares down 5% premarket</a></h4><ul>\n<li>Agios Pharmaceuticals (NASDAQ:<a href=\"https://seekingalpha.com/symbol/AGIO\" title=\"Agios Pharmaceuticals, Inc.\">AGIO</a>) eases <font color=\"red\">5%</font> premarket on light volume in response to its announcement of a $150M public offering of common stock. Price, volume and terms have yet to be announced.</li>\n<li>\n<strong>Update</strong>: On September 15, the company announced that it priced its offering of 3,370,786 shares at $44.50. Underwriters over-allotment is an additional 505,617 shares. Closing date is September 20.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3208693\" data-linked=\"Agios Pharma launches equity offering; shares down 5% premarket\" data-tweet=\"$AGIO - Agios Pharma launches equity offering; shares down 5% premarket https://seekingalpha.com/news/3208693-agios-pharma-launches-equity-offering-shares-down-5-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3208693-agios-pharma-launches-equity-offering-shares-down-5-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208674\" data-ts=\"1473856020\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGN\" target=\"_blank\">AGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208674-allergan-buys-vitae-pharmaceuticals-for-21-share\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Allergan buys Vitae Pharmaceuticals for $21 a share</a></h4><ul>\n<li>Allergan plc (NYSE:<a href=\"https://seekingalpha.com/symbol/AGN\" title=\"Allergan plc\">AGN</a>) inks a deal to acquire Vitae Pharmaceuticals (NASDAQ:<a href=\"https://seekingalpha.com/symbol/VTAE\" title=\"Vitae Pharmaceuticals\">VTAE</a>) for ~$639M in cash or $21 a share, almost a 160% premium to yesterday's close of $8.10.</li>\n<li>The transaction beefs up Allergan's dermatology pipeline with the addition of VTP-43742, a retinoic acid receptor-related orphan receptor gamma inhibitor for the treatment of psoriasis and other autoimmune disorders and VTP-38543, a topical Liver X receptor beta selective agonist for the treatment of atopic dermatitis.</li>\n<li>The deal should close by year end.</li>\n<li>Read now <a href=\"https://seekingalpha.com/article/3962961-vitae-pharmaceuticals-go-long\" target=\"_blank\">Vitae Pharmaceuticals: Go Long?</a>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3208674\" data-linked=\"Allergan buys Vitae Pharmaceuticals for $21 a share\" data-tweet=\"$AGN $AGN $VTAE - Allergan buys Vitae Pharmaceuticals for $21 a share https://seekingalpha.com/news/3208674-allergan-buys-vitae-pharmaceuticals-for-21-share?source=tweet\" data-url=\"https://seekingalpha.com/news/3208674-allergan-buys-vitae-pharmaceuticals-for-21-share\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208670\" data-ts=\"1473855515\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBRL\" target=\"_blank\">CBRL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208670-cracker-barrel-lower-after-guidance-misses-expectations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cracker Barrel lower after guidance misses expectations</a></h4><ul> <li>Cracker Barrel (NASDAQ:<a href=\"https://seekingalpha.com/symbol/CBRL\" title=\"Cracker Barrel Old Country Store, Inc.\">CBRL</a>) reports a 3.2% gain in comparable sales during FQ4. A 4.4% increase in average check helped to offset a 1.2% drop in store traffic during the period. Traffic and sales were at their lowest during July.</li> <li>The average menu price increase for the quarter was approximately 2.4%.</li> <li>Comparable retail sales came in at +3.5%.</li> <li>Operating income as a percentage of total sales improved 30 bps to 10.4%. Lower general and administrative expenses and cost of goods sold were partially offset by a jump in store operating expenses.</li> <li>Cracker Barrel expects FY17 EPS of $7.95-$8.10 vs. $8.33 consensus.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3208664-cracker-barrel-misses-0_01-beats-revenue\" target=\"_blank\">Cracker Barrel misses by $0.01, beats on revenue</a> (Sept. 14)</li> <li>CBRL <font color=\"red\">-2.01%</font> premarket to $147.50.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3208670\" data-linked=\"Cracker Barrel lower after guidance misses expectations\" data-tweet=\"$CBRL - Cracker Barrel lower after guidance misses expectations https://seekingalpha.com/news/3208670-cracker-barrel-lower-after-guidance-misses-expectations?source=tweet\" data-url=\"https://seekingalpha.com/news/3208670-cracker-barrel-lower-after-guidance-misses-expectations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208667\" data-ts=\"1473854928\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRPT\" target=\"_blank\">SRPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208667-sarepta-ahead-14-premarket-on-speculation-approval-may-be-imminent\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sarepta ahead 14% premarket on speculation that approval may be imminent</a></h4><ul>\n<li>Sarepta Therapeutics (NASDAQ:<a href=\"https://seekingalpha.com/symbol/SRPT\" title=\"Sarepta Therapeutics, Inc.\">SRPT</a>) is up <font color=\"green\">14%</font> premarket on increased volume stoked by speculation that FDA approval may finally be at hand. Apparently traders are taking positions based on the rumor that eteplirsen reviewer Ron Farkas has left the agency. He was the most direct in his opinion that the company had not submitted sufficient data to prove the efficacy of eteplirsen for the treatment of Duchenne muscular dystrophy. Traders appear to be making the leap that his departure, if true, was prompted by his opposition to the impending approval of eteplirsen.</li>\n<li>Read now <a href=\"https://seekingalpha.com/article/3998733-sarepta-competition-gate\" target=\"_blank\">Sarepta: The Competition Is At The Gate</a>\n</li>\n<li>\n<strong>Update</strong>: Yesterday evening, Benzinga <a href=\"http://www.benzinga.com/general/biotech/16/09/8455408/exclusive-dr-ron-farkas-eteplirsens-harshest-critic-has-left-the-fda\" target=\"_blank\">reported </a>that Dr. Farkas has, indeed, left the FDA. His last day was supposedly September 9. According to a <a href=\"http://www.benzinga.com/news/16/09/8457826/parexel-spokesperson-confirms-to-benzinga-ron-farkas-joined-co-earlier-this-month\" target=\"_blank\">later post</a> by Benzinga, Farkas joined life sciences consulting firm <a href=\"https://www.parexel.com/\" target=\"_blank\">PAREXEL</a> (<a href=\"https://seekingalpha.com/symbol/PRLX\" title=\"Parallax Health Sciences Inc.\">OTCPK:PRLX</a>).</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3208667\" data-linked=\"Sarepta ahead 14% premarket on speculation that approval may be imminent\" data-tweet=\"$SRPT $SRPT $PRLX - Sarepta ahead 14% premarket on speculation that approval may be imminent https://seekingalpha.com/news/3208667-sarepta-ahead-14-premarket-on-speculation-approval-may-be-imminent?source=tweet\" data-url=\"https://seekingalpha.com/news/3208667-sarepta-ahead-14-premarket-on-speculation-approval-may-be-imminent\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208638\" data-ts=\"1473852338\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TPR\" target=\"_blank\">TPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208638-morgan-stanley-warns-on-margins-coach\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley warns on margins at Coach</a></h4><ul> <li>Morgan Stanley <a href=\"http://www.streetinsider.com/Downgrades/Morgan+Stanley+Downgrades+Coach+%28COH%29+to+Underweight/12030219.html\" target=\"_blank\">downgrades</a> Coach (COH) to an Underweight rating after having the stock set at Equalweight.</li> <li>Analyst Kimberly Greenberger raises concerns over the sharp drop in merchandise margins at the luxury chain due to a high level of promotional activity in the outlet channel.</li>\n<li>The investment firm lowers its price target to $32 vs. the 52-week Coach trading range of $27.22 to $43.71.</li> <li>COH <font color=\"red\">-2.37%</font> premarket to $35.43.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3208638\" data-linked=\"Morgan Stanley warns on margins at Coach\" data-tweet=\"$TPR - Morgan Stanley warns on margins at Coach https://seekingalpha.com/news/3208638-morgan-stanley-warns-on-margins-coach?source=tweet\" data-url=\"https://seekingalpha.com/news/3208638-morgan-stanley-warns-on-margins-coach\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208636\" data-ts=\"1473851954\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXEL\" target=\"_blank\">EXEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208636-exelixis-cabometyx-approved-in-europe-for-kidney-cancer-shares-up-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Exelixis&#39; Cabometyx approved in Europe for kidney cancer; shares up 1% premarket</a></h4><ul>\n<li>Exelixis (NASDAQ:<a href=\"https://seekingalpha.com/symbol/EXEL\" title=\"Exelixis, Inc.\">EXEL</a>) is up a modest <font color=\"green\">1%</font> premarket on light volume in response to its announcement that the European Commission has approved <a href=\"https://www.cabometyx.com/\" target=\"_blank\">CABOMETYX</a> (cabozantinib) for the treatment of adult patients with advanced renal cell carcinoma (RCC) who have received prior vascular endothelial growth factor (VEGF)-targeted therapy. The approval was expected following a positive Ad Comm vote in July.</li>\n<li>The action triggers a $60M milestone payment from licensee Ipsen (<a href=\"https://seekingalpha.com/symbol/IPSEY\" title=\"Ipsen S.A. ADR\">OTCPK:IPSEY</a>)(<a href=\"https://seekingalpha.com/symbol/IPSEF\" title=\"Ipsen S.A.\">OTCPK:IPSEF</a>) who has commercialization rights worldwide excluding the U.S., Canada and Japan.</li>\n<li>The FDA approved the RCC indication in April.</li>\n<li>Cabozantinib inhibits enzymes called tyrosine kinases, which play roles in the proliferation and survival of cancer cells.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3208636\" data-linked=\"Exelixis&#39; Cabometyx approved in Europe for kidney cancer; shares up 1% premarket\" data-tweet=\"$EXEL $EXEL $IPSEY - Exelixis&#39; Cabometyx approved in Europe for kidney cancer; shares up 1% premarket https://seekingalpha.com/news/3208636-exelixis-cabometyx-approved-in-europe-for-kidney-cancer-shares-up-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3208636-exelixis-cabometyx-approved-in-europe-for-kidney-cancer-shares-up-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3208633\" data-ts=\"1473851150\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPPI\" target=\"_blank\">SPPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3208633-ad-comm-review-today-for-spectrum-pharmas-apaziquone\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ad Comm review today for Spectrum Pharma&#39;s apaziquone</a></h4><ul>\n<li>The FDA's Oncologic Drugs Advisory Committee <a href=\"http://www.fda.gov/AdvisoryCommittees/Calendar/ucm513937.htm\" target=\"_blank\">meets today</a> to review and discuss Spectrum Pharmaceuticals' (NASDAQ:<a href=\"https://seekingalpha.com/symbol/SPPI\" title=\"Spectrum Pharmaceuticals, Inc.\">SPPI</a>) New Drug Application (NDA) seeking approval of apaziquone, branded as Qapzola, for the immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer.</li>\n<li><a href=\"http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM520089.pdf\" target=\"_blank\">Draft questions</a></li>\n<li><a href=\"http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM520093.pdf\" target=\"_blank\">FDA briefing doc</a></li>\n<li><a href=\"http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM520094.pdf\" target=\"_blank\">Spectrum briefing doc</a></li>\n<li>\n<strong>Update</strong>: The panel voted 14 - 0 against approval.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3208633\" data-linked=\"Ad Comm review today for Spectrum Pharma&#39;s apaziquone\" data-tweet=\"$SPPI - Ad Comm review today for Spectrum Pharma&#39;s apaziquone https://seekingalpha.com/news/3208633-ad-comm-review-today-for-spectrum-pharmas-apaziquone?source=tweet\" data-url=\"https://seekingalpha.com/news/3208633-ad-comm-review-today-for-spectrum-pharmas-apaziquone\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":49,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}